Top

Annals of Nuclear Medicine

Published in:

01-12-2015 | Original Article

Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT?

Authors: Daniele Di Biagio, Agostino Chiaravalloti, Mario Tavolozza, Paolo Abbatiello, Orazio Schillaci

Published in: Annals of Nuclear Medicine | Issue 10/2015

Abstract

Aim

To investigate the diagnostic performance of early acquisition compared to late imaging for the detection of local recurrence of prostate cancer by means of ¹⁸F-FCH PET/CT.

Materials and methods

99 patients with radical prostatectomy (mean PSA 3.9 ± 5.03) were subjected to early dynamic PET/CT acquisition of the pelvis and a whole body PET/CT in the same exam session. None of the patients examined was subjected to radiotherapy for local or distant recurrence. All the subjects were taken off hormonal therapy.

Results

58 subjects did not show local recurrence in both early and late acquisition, 22 were positive in both modalities, 10 showed a positive early and a negative late acquisition while 9 showed a negative early and a positive late acquisition (Cohen’s k = 0.558). When the results of imaging modalities were considered separately, sensitivity, specificity, positive predictive value and negative predictive value resulted: 78.9, 96.7, 93.8 and 88.1 % for early acquisition and 73.7, 95.1, 90.3 and 85.3 % for late acquisition, respectively. When the results of early and late acquisition were considered together, results were 97.4, 93.4, 90.2 and 98.3 %, respectively.

Conclusions

The combination of early acquisition with late acquisition lead to an increase of the diagnostic accuracy of ¹⁸F-FCH PET/CT for the diagnosis of local recurrence in prostate cancer.

Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24(2):395–406.CrossRefPubMed

Gustafson GS, Nguyen PL, Assimos DG, D’Amico AV, Gottschalk AR, Hsu IC, et al. ACR appropriateness criteria(R) postradical prostatectomy irradiation in prostate cancer: Oncology (Williston Park). 2014;28(12). [pii]: 202938.

Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113(6):895–904.CrossRefPubMed

Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253–63.CrossRefPubMed

Mansi L, Virgolini I. Diagnosis and therapy are walking together on radiopeptides’ avenue. Eur J Nucl Med Mol Imaging. 2011;38(4):605–12.CrossRefPubMed

Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L. F-fluorometilcholine or F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. Nucl Med Biol. 2015;42(4):340–8.CrossRefPubMed

Mansi L, Cuccurullo V, Evangelista L. Is radiocholine PET/CT already clinically useful in patients with prostate cancer? J Nucl Med. 2014;55(9):1401–3.CrossRefPubMed

Kwee SA, DeGrado T. Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels. Eur J Nucl Med Mol Imaging. 2008;35(8):1567–9.CrossRefPubMed

DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61(1):110–7.PubMed

10.

Evangelista L, Zattoni F, Guttilla A, Saladini G, Colletti PM, Rubello D. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38(5):305–14.CrossRefPubMed

11.

Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81(4):700–8.CrossRefPubMed

12.

Calabria F, Chiaravalloti A, Schillaci O. (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer. Clin Nucl Med. 2014;39(2):122–30.PubMed

13.

Massaro A, Ferretti A, Secchiero C, Cittadin S, Milan E, Tamiso L, et al. Optimising (18)F-choline PET/CT acquisition protocol in prostate cancer patients. N Am J Med Sci. 2012;4(9):416–20.PubMedCentralCrossRefPubMed

14.

Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47(2):262–9.PubMed

15.

Chondrogiannis S, Marzola MC, Grassetto G, Maffione AM, Rampin L, Veronese E, et al. New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization. Biomed Res Int. 2014;215650(10):10.

16.

Puri KS, Suresh KR, Gogtay NJ, Thatte UM. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009;55(2):131–4.CrossRefPubMed

17.

Calabria F, Chiaravalloti A, Tavolozza M, Ragano-Caracciolo C, Schillaci O. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection? Nucl Med Commun. 2013;34(8):733–40.CrossRefPubMed

18.

Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55(2):223–32.CrossRefPubMed

19.

Bertagna F, Abuhilal M, Bosio G, Simeone C, Rossini P, Pizzocaro C, et al. Role of (1)(1)C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation. Jpn J Radiol. 2011;29(6):394–404.CrossRefPubMed

20.

Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52(2):423–9.CrossRefPubMed

21.

Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39(1):13–26.CrossRefPubMed

22.

DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43(1):92–6.PubMed

23.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99(6):1415–20.CrossRefPubMed

24.

Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35(1):9–17.CrossRefPubMed

25.

D’Angelillo RM, Sciuto R, Ramella S, Papalia R, Jereczek-Fossa BA, Trodella LE, et al. (1)(8)F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients. Int J Radiat Oncol Biol Phys. 2014;90(2):296–302.CrossRefPubMed

26.

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54(6):833–40.CrossRefPubMed

27.

Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med. 2012;26(6):501–7.PubMedCentralCrossRefPubMed

28.

Henriksen G, Herz M, Hauser A, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC). Nucl Med Biol. 2004;31(7):851–8.CrossRefPubMed

29.

Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology. 1999;54(6):1044–8.CrossRefPubMed

30.

Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219(2):432–9.CrossRefPubMed

Title: Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early 18F-FCH PET/CT?
Authors: Daniele Di Biagio
Agostino Chiaravalloti
Mario Tavolozza
Paolo Abbatiello
Orazio Schillaci
Publication date: 01-12-2015
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 10/2015
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-015-1015-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT?

Abstract

Aim

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer

Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?

Validation of prone myocardial perfusion SPECT with a variable-focus collimator versus supine myocardial perfusion SPECT with or without computed tomography-derived attenuation correction

Comparison of ultrasonography features and malignancy rate of toxic and nontoxic autonomous nodules: a preliminary study

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT

18F-FPRGD2 PET/CT imaging of musculoskeletal disorders